Management of relapsing–remitting multiple sclerosis in Qatar: an expert consensus
Open Access
- 7 October 2019
- journal article
- review article
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 36 (2), 251-260
- https://doi.org/10.1080/03007995.2019.1669378
Abstract
Healthcare systems vary greatly between countries. International, evidence-based guidelines for the management of multiple sclerosis (MS) may need to be adapted for use in particular countries. Two years ago, the authors published a comprehensive consensus guideline for the management of MS in Qatar. Since that time, the availability of disease-modifying treatments for relapsing-remitting MS (RRMS), and our understanding of how to apply those treatments, has increased. The authors present an update to our guidance, focussing on the management of relapsing-remitting RRMS. In particular, the authors consider the optimal use of different DMTs in patients presenting with mild, medium or high disease activity.Keywords
This publication has 71 references indexed in Scilit:
- Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?Therapeutics and Clinical Risk Management, 2013
- Subcutaneous Recombinant Interferon-β-1a (Rebif®)Drugs, 2011
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid ArthritisArchives of Neurology, 2011
- Evidence-based guideline update: Plasmapheresis in neurologic disordersNeurology, 2011
- Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal LeukoencephalopathyThe Oncologist, 2010
- Glatiramer AcetateDrugs, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Managing the Adverse Effects of Interferon-?? Therapy in Multiple SclerosisDrug Safety, 2000
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995